布仑妥昔单抗维多汀
医学
间变性大细胞淋巴瘤
依托泊苷
强的松
内科学
肿瘤科
环磷酰胺
长春新碱
CD30
癌症研究
化疗
淋巴瘤
作者
Alex Francisco Herrera,Jasmine M. Zain,Kerry J. J. Savage,Tatyana A. Feldman,Jonathan Edward Brammer,Lu Chen,Sandrine Puverel,Leslie L. Popplewell,Lihua Elizabeth Budde,Matthew Genyeh Mei,Chitra M. Hosing,Ranjit K. Nair,Lori Ann Leslie,Shari Daniels,Lacolle Peters,Stephen J. Forman,Steven T. Rosen,Larry W. Kwak,Swaminathan P. Iyer
标识
DOI:10.1016/s2352-3026(24)00171-6
摘要
CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some other peripheral T-cell lymphoma subtypes. Incorporation of brentuximab vedotin into initial therapy for people with CD30-positive peripheral T-cell lymphomas prolonged progression-free survival, but there is room for improvement, especially for people with non-anaplastic large-cell lymphoma subtypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI